再同期療法による刺激部位が,心不全患者の心収縮機能に与える影響
C Butter1, A Auricchio, C Stellbrink
1German Heart Institute and Charité, Campus Virchow Klinikum, Berlin, Germany.
Circulation
|December 19, 2001
まとめ
左心室 (LV) の自由壁刺激を用いた心臓再同期療法 (CRT) は,前壁刺激と比較して心臓の機能を大幅に改善します. この発見は,心不全の患者のより良い結果のために最適なLVリード配置の重要性を強調しています.
科学分野:
- 心臓病学 心臓病学
- バイオメディカルエンジニアリング
- 心不全管理について
背景:
- 心臓再同期療法 (CRT) は,導電遅延の心不全患者の静脈動脈機能を改善します.
- 最適な左心室 (LV) のリード配置はCRTの有効性にとって不可欠ですが,部位特有の血液動力学的効果は十分に確立されていません.
研究 の 目的:
- 2つの異なるLV刺激部位を用いてCRTに対する血液動力学的反応を比較する:自由壁対前壁.
- CRT中のシストリックパフォーマンスに対するLV刺激部位の影響を決定する.
主な方法:
- PATH-CHF-II試験の30人の心不全患者 (NYHAクラス2.7,QRS 152 ms) が研究されました.
- CRTは,様々なAV遅延でLVと二心房 (BV) 刺激で提供され,LV導線は自由壁または前壁に配置されました.
- LV dP/dt (max) と大動脈脈圧を含む血液動力学的パラメータを測定し,刺激部位を比較した.
主要な成果:
- LVフリーウォール刺激は,前壁刺激と比較して,LV dP/dt(max) (14%対6%のLV; 12%対5%のBV) と脈圧 (8%対4%のLV; 9%対5%のBV) の有意な増加をもたらしました.
- 患者のサブセット (三分の一) は,前壁刺激でLVシストリック機能の低下を経験したが,自由壁刺激は一貫して改善した.
結論:
- CRT中の左心室自由壁刺激は,前壁刺激と比較して,LVのシストリックパフォーマンスを大幅に改善します.
- これらの発見は,LVフリー壁がCRT鉛置換のための優れた場所であることを示唆しており,長期的な臨床的利益のためのさらなる調査を正当化しています.
関連する概念動画
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.


